SCHEMBL4765573

SCHEMBL4765573

CCCOC1OCCO[C]1c1cccc2ccccc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 2/20 0.36
HTR1A P08908 1/20 0.36
HTR2B P41595 1/20 0.36
TMEM97 Q5BJF2 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
MAPT P10636 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ALOX15 P16050 4/20 0.35
SLC6A4 P31645 2/20 0.33
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 2/20 0.33
GLA P06280 2/20 0.33
GAA P10253 2/20 0.33
CHRNB4 P30926 1/20 0.33
CHRNA3 P32297 1/20 0.33
CHRNA7 P36544 1/20 0.33
DRD2 P14416 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4765802 0.93 ALOX15 (0.37) HTR7HTR1AHTR2BTMEM97SIGMAR1
SCHEMBL4722801 0.90 HTR7 (0.40) HTR7HTR1AHTR2BTMEM97SIGMAR1
SCHEMBL4721176 0.82 MAPT (0.39) HTR7HTR1AHTR2BTMEM97SIGMAR1
SCHEMBL4720577 0.78 MEN1 (0.33) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL4720031 0.70 LTA4H (0.35) ALDH1A1GAA
SCHEMBL4723715 0.70 NPC1 (0.39) HTR7MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL4721318 0.66 KDM4E (0.33) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL4722810 0.66 CHRNB4 (0.34) HTR7MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL3237232 0.63 NISCH (0.46) MAPTNPC1RAB9ASMN1; SMN2ALOX15
Tetradecane SCHEMBL9931525 0.63 CNR1 (0.51) MAPTNPC1RAB9ASMN1; SMN2ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 HTR7 136/4885HTR1A 93/4885HTR2B 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.